[1] SKOLARIKOS A, JUNG H, NEISIUS A, et al. EAU Guidelines on urolithiasis [J]. European Association of Urology Guidelines 2023 edition, 2023: 1-120. https://d56bochluxqnz.cloudfront.net/documents/ full-guideline/ EAU-Guidelines-on-Urolithiasis-2023.pdf.
[2] GERAGHTY R M, DAVIS N F, TZELVES L, et al. Best practice in interventional management of urolithiasis: an update from the European association of urology guidelines panel for urolithiasis 2022[J]. Eur Urol Focus, 2023, 9(1):199-208. doi:  10.1016/j.euf.2022.06.014
[3] 泌尿外科手术部位感染预防中国专家共识编写组. 泌尿外科手术部位感染预防中国专家共识(2019版)[J]. 中华泌尿外科杂志, 2019, 40(6):401-404. doi:  10.3760/cma.j.issn.1000-6702.2019.06.001
[4] 上尿路结石围手术期感染控制及抗菌药物应用专家意见编写组. 上尿路结石患者围手术期感染控制及抗菌药物应用专家意见(2023版)[J]. 中华泌尿外科杂志, 2023, 44(7):481-485.
[5]

BONKAT G, BARTOLETTI R, BRURUYÈRE F, et al. EAU Guidelines on Urological Infections[J]. European Association of Urology Guidelines 2023 edition, 2023: 1-84.
[6] 乔庐东, 陈山, 马小军, 等. 上尿路结石患者围手术期抗菌药物应用的专家意见[J]. 中华泌尿外科杂志, 2017, 38(9):641-643.
[7]

CHEN D, JIANG C H, LIANG X F, et al. Early and rapid prediction of postoperative infections following percutaneous nephrolithotomy in patients with complex kidney stones[J]. BJU Int, 2019, 123(6):1041-1047. doi:  10.1111/bju.14484
[8]

ZHOU G M, ZHOU Y, CHEN R, et al. The influencing factors of infectious complications after percutaneous nephrolithotomy: a systematic review and meta-analysis[J]. Urolithiasis, 2022, 51(1):17. doi:  10.1007/s00240-022-01376-5
[9] 邵燕, 刘群, 张东萍, 等. 我院特殊诊疗操作中预防性使用抗菌药物调查分析[J]. 中国药房, 2017, 28(26):3624-3627. doi:  10.6039/j.issn.1001-0408.2017.26.07
[10] 国卫办医发[2015]43号附件. 抗菌药物临床应用指导原则(2015年版). (2015-08-27)[2023-07-01]. https://www.gov.cn/xinwen/2015-08/27/content_2920799.htm.
[11]

WOLF J S Jr, BENNETT C J, DMOCHOWSKI R R, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis[J]. J Urol, 2008, 179(4):1379-1390. doi:  10.1016/j.juro.2008.01.068
[12]

NABER KG. SCHAEFFER AJ. HEYNS CF, et a1. EAU-ICUD Urogenital infections [M]. First edition. The Netherlands: European Association of Urology-International Consultation on Urological Diseases, 2010: 645-710.
[13]

PORTSMOUTH S, VAN VEENHUYZEN D, ECHOLS R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial[J]. Lancet Infect Dis, 2018, 18(12):1319-1328. doi:  10.1016/S1473-3099(18)30554-1
[14]

TAN X M, PAN Q W, MO C G, et al. Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: a systematic review and network meta-analysis[J]. Medicine, 2020, 99(2):e18769. doi:  10.1097/MD.0000000000018769
[15] 黄茹润. 碳青霉烯类抗菌药物治疗复杂性尿路感染疗效和安全性的Meta分析[D]. 大理: 大理大学, 2021.